Company Overview and News
Americans continued their shopping spree buoyed by strengthening labor market, tax reform and rising incomes. U.S. retail sales rose again in the month of May, clearly indicating that the economy remains well on track after a muted start to the year. These factors along with firming inflation allowed the Federal Reserve to raise the benchmark interest rate for the second time this year. Consumers are splurging on clothing, flocking department stores and buying motor vehicles, even as they shell out more for gasoline.
DDS SPG.PRJ SCVL SPG URBN LAD
Investors interested in Retail-Wholesale stocks should always be looking to find the best-performing companies in the group. Is Dillard's (DDS - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Retail-Wholesale peers, we might be able to answer that question.
Dillard’s, Inc. (DDS - Free Report) appears quite promising backed by its growth strategies, unique merchandise offerings and impressive first-quarter fiscal 2018 results. Notably, Dillard’s shares hit a 52-week high of $94.43 on Jun 8, though it closed a tad lower at $93.84. This uptrend can be attributed to the company’s solid start to fiscal 2018. In the fiscal first quarter, both earnings and revenues outpaced the estimates and improved year over year.
DDS CHJHF BKE CHA 0728 URBN FOSL
As of late, it has definitely been a great time to be an investor in Dillard's, Inc. (DDS - Free Report) . The stock has moved higher by 32.8% in the past month, while it is also above its 20 Day SMA too. This combination of strong price performance and favorable technical, could suggest that the stock may be on the right path.
COF.PRG DDS COF.PRH COF-P COF.WS COF.PRP COF COF-D COF-C COF-F COF.PRC GNW OXY COF.PRD COF.PRF
Nearly an hour before its release, President Trump tweeted that he was “looking forward” to May’s jobs data. Ultimately, the report was able to live up to investors’ expectations, heightened primarily by Trump’s comments. The unemployment rate declined to the lowest level witnessed since April 2000. Job additions also increased substantially.
MTZ DDS JEC SCVL ENSG CHE
A sizable portion of the consumer space, and the retail industry, in particular, has been partially disrupted by the fast expansion of pure e-commerce players with aggressive business models. You will not be surprised to know I am talking about Amazon (AMZN) and other online retailers that replicate, at least in part, Amazon's business model. The threat of Amazon and its aggressive business model where the company sacrifices all the profits in order to gain market share is well known.
DDS FB YUM TPR CTRP TRIP M GME EXPE BKNG JWN NKE GRUB AAPL DKS SNE FL MCD
Stocks were indicated to open higher now that certain tariffs have been lightened up or suspended during trade negotiations. The trend of endlessly buying the dips has not worked as well as it has in prior years and many investors have considered how they want their investments positioned for the longer term.
DDS AMAG CPB HCP MS.PRE MS.PRF MS.PRG MS.PRA TWNK APPF MS.PRI MS.PRK AMAT CDAY HEAR TRI ENR FLO MS
Shares of Dillard's Inc. (DDS - Free Report) gained 6.3% yesterday after the company reported robust first-quarter fiscal 2018 results. The company’s top and bottom line outpaced the Zacks Consensus Estimate and improved year over year. In fact, this marked its third straight quarter of positive earnings surprise with fourth consecutive sales beat. Moreover, Dillard's constant efforts to capitalize on growth opportunities in its brick-and-mortar stores and e-commerce business remain encouraging.
DDS JWN DG BKE
3h - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
as of ET